The effect of CYP2C19 polymorphism on the pharmacokinetics and acid-inhibitory effects of oral lansoprazole and omeprazole

被引：0
|
作者：
Bekkers, CHJ
Touw, DJ
Lamers, CBHW
Geus, WP
机构：
[1] Hague Cent Pharm, The Hague, Netherlands
[2] Leiden Univ, Med Ctr, NL-2300 RA Leiden, Netherlands
[3] Leyenburg Hosp, The Hague, Netherlands
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2002年 / 54卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：553 / 553
页数：1
相关论文
共 50 条
  • [31] Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects
    Chang‑Keun Cho
    Ji-Young Byeon
    Pureum Kang
    Hye-Jung Park
    Eunvin Ko
    Chou Yen Mu
    Choon-Gon Jang
    Seok-Yong Lee
    Yun Jeong Lee
    Archives of Pharmacal Research, 2023, 46 : 111 - 116
  • [32] The effect of CYP2C19 activity on pharmacokinetics of lansoprazole and its active metabolites in healthy subjects
    Xu, Hong-Rong
    Chen, Wei-Li
    Li, Xue-Ning
    Chu, Nan-Nan
    PHARMACEUTICAL BIOLOGY, 2010, 48 (08) : 947 - 952
  • [33] CYP2C19 Mediates the Inhibitory Effect of Sinomenine on Cyclophosphamide Pharmacokinetics in Rats
    Li, Bing
    Li, Wei
    LATIN AMERICAN JOURNAL OF PHARMACY, 2022, 41 (07): : 1295 - 1299
  • [34] Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Rosuvastatin in Healthy Taiwanese Subjects
    Finkelman, Richard D.
    Wang, Tzung-Dau
    Wang, Yi
    Azumaya, Connie T.
    Birmingham, Bruce K.
    Wissmar, Jenny
    Mosqueda-Garcia, Rogelio
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2015, 4 (01): : 33 - 40
  • [35] Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes
    Yu-rong HU
    ActaPharmacologicaSinica, 2004, (08) : 12 - 16
  • [36] Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes
    Hu, YR
    Qiao, HL
    Kan, QC
    ACTA PHARMACOLOGICA SINICA, 2004, 25 (08) : 986 - 990
  • [37] Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19.
    Yim, DS
    Yu, KS
    Cho, JY
    Park, SS
    Shin, SG
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P72 - P72
  • [38] Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19
    Yu, BN
    Chen, GL
    He, N
    Ouyang, DS
    Chen, XP
    Liu, ZQ
    Zhou, HH
    DRUG METABOLISM AND DISPOSITION, 2003, 31 (10) : 1255 - 1259
  • [39] Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19
    Wang, JH
    Liu, ZQ
    Wang, W
    Chen, XP
    Shu, Y
    He, N
    Zhou, HH
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (01) : 42 - 47
  • [40] Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people (vol 32, pg 517, 2007)
    Hu, Xiang-peng
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2007, 32 (06) : 659 - 659
12345